Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Australasian Leukaemia and Lymphoma Group (ALLG)
Scientific Title
ALLG NHL26
A Phase 2 Study of patients treated for relapsed Follicular Lymphoma: with Revlimid (Registered Trademark) consolidation added to Rituximab maintenance therapy in those remaining Positron Emission Tomography (PET) positive